2.73

15.68% 0.37

After Hours: 2.71 -0.02 -0.73%

Inhibikase Therapeutics Inc (IKT)

Overview News Price History Financials Discussions Forecast Stock Split

Inhibikase Therapeutics Inc stock is traded at $2.73, with a volume of 293.85K. It is up +15.68% in the last 24 hours and up +12.81% over the past month. Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Previous Close:

$2.36

Open:

$2.4

24h Volume:

293.85K

Relative Volume:

0.61

Market Cap:

$169.33M

Revenue:

Net Income/Loss:

$-19.20M

P/E Ratio:

-0.6547

EPS:

-4.17

Net Cash Flow:

$-15.98M

1W Performance:

+37.88%

1M Performance:

+12.81%

6M Performance:

+50.83%

1Y Performance:

+206.74%

1-Day Range:

$2.39

$2.8647

1-Week Range:

$1.75

$2.8647

52-Week Range:

$0.85

$3.82

Inhibikase Therapeutics Inc Stock (IKT) Company Profile

Name

Inhibikase Therapeutics Inc

Sector

Healthcare (1200)

Industry

Biotechnology (682)

Phone

678-392-3419

Address

3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA

Employee

Twitter

Next Earnings Date

2024-11-12

Latest SEC Filings

IKT's Discussions on Twitter

Compare IKT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IKT Inhibikase Therapeutics Inc	2.73	169.33M	0	-19.20M	-15.98M	-4.17
VRTX Vertex Pharmaceuticals Inc	464.56	119.70B	10.63B	-479.80M	-1.35B	13.33
REGN Regeneron Pharmaceuticals Inc	754.87	82.75B	13.85B	4.65B	3.32B	35.06
ARGX Argen X Se Adr	614.59	36.73B	1.86B	-40.29M	-1.28B	-4.16
ALNY Alnylam Pharmaceuticals Inc	253.74	32.53B	2.09B	-332.26M	16.06M	-4.14
BNTX Biontech Se Adr	120.72	28.50B	3.30B	-501.07M	1.03B	11.54

Inhibikase Therapeutics Inc Stock (IKT) Latest News

Nov 19, 2024

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients - Seeking Alpha

Nov 19, 2024

Nov 18, 2024

Inhibikase Therapeutics files to sell 58.31M shares of common stock for holders - TipRanks

Nov 18, 2024

Nov 15, 2024

ARMISTICE CAPITAL, LLC Expands Stake in Inhibikase Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity - The Bakersfield Californian

Nov 14, 2024

Inhibikase Secures $275M Financing Deal, Advances PAH Drug Trial Despite Q3 Loss | IKT Stock News - StockTitan

Nov 14, 2024

Nov 08, 2024

Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential - Investing.com

Nov 08, 2024

Jefferies starts Inhibikase Therapeutics shares with Buy on drug potential By Investing.com - Investing.com Canada

Nov 08, 2024

Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024

Oct 24, 2024

Hedge Fund and Insider Trading News: D.E. Shaw, David Einhorn, Bill Ackman, Crispin Odey, Ken Griffin, Elliott Investment Management, Bridgewater Associates, Inhibikase Therapeutics Inc (IKT), Micron Technology Inc (MU), and More - Insider Monkey

Oct 24, 2024

Inhibikase therapeutics director Amit Munshi buys $500k in shares By Investing.com - Investing.com Nigeria

Oct 24, 2024

Director Arvind Kush Acquires 145,000 Shares of Inhibikase Thera - GuruFocus.com

Oct 24, 2024

Oct 23, 2024

Inhibikase therapeutics director Amit Munshi buys $500k in shares - Investing.com India

Oct 23, 2024

Inhibikase Therapeutics director Bellini acquires $2m in stock - Investing.com India

Oct 23, 2024

Inhibikase Therapeutics director Bellini acquires $2m in stock By Investing.com - Investing.com South Africa

Oct 23, 2024

Inhibikase therapeutics director Kush Arvind buys $198,650 in stock - Investing.com

Oct 23, 2024

Inhibikase Therapeutics Secures Funding and Strengthens Leadership - Yahoo Finance

Oct 23, 2024

Inhibikase (IKT) Stock Climbs After-Market Following Key Financing - Stocks Telegraph

Oct 23, 2024

Oct 22, 2024

Perceptive Advisors LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance

Oct 22, 2024

Perceptive Advisors LLC Acquires New Stake in Inhibikase Therape - GuruFocus.com

Oct 22, 2024

Inhibikase Therapeutics stock rises after pricing $110M private offering - MSN

Oct 22, 2024

Oct 21, 2024

IKTInhibikase Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Oct 21, 2024

Inhibikase Therapeutics Announces Closing of up to $275 - GlobeNewswire

Oct 21, 2024

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension - StockTitan

Oct 21, 2024

Oct 18, 2024

Fairmount Funds Management LLC Acquires New Stake in Inhibikase Therapeutics Inc - Yahoo Finance

Oct 18, 2024

Oct 14, 2024

Inhibikase Therapeutics’ $110 Million Private Placement - Global Legal Chronicle

Oct 14, 2024

Analyzing the Impact of Earnings Reports on Inhibikase Therapeutics Inc Inc. (IKT) Price Performance - The InvestChronicle

Oct 14, 2024

500: Something went wrong - Investing.com

Oct 14, 2024

Oct 11, 2024

Inhibikase Therapeutics Secures $110M for Drug Development - Yahoo Finance

Oct 11, 2024

Steven Cohen's Strategic Acquisition of Inhibikase Therapeutics Shares - GuruFocus.com

Oct 11, 2024